{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:30:54Z","timestamp":1782855054736,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"sanofi employee"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0447-y","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T17:10:38Z","timestamp":1543425038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["SAR228810: an antibody for protofibrillar amyloid \u03b2 peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-0951","authenticated-orcid":false,"given":"Laurent","family":"Pradier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Blanchard-Br\u00e9geon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrees","family":"Bohme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Debeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Menager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Barneoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Taupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dugay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souad","family":"Naimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Duchesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Gagnaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Weeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Travaline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Khiroug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Slaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Ravetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Canton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"issue":"114","key":"447_CR1","doi-asserted-by":"publisher","first-page":"114ps48","DOI":"10.1126\/scitranslmed.3003529","volume":"3","author":"DM Holtzman","year":"2011","unstructured":"Holtzman DM, et al. Mapping the road forward in Alzheimer\u2019s disease. Sci Transl Med. 2011;3(114):114ps48.","journal-title":"Sci Transl Med"},{"issue":"2","key":"447_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.neuron.2010.10.013","volume":"68","author":"L Bertram","year":"2010","unstructured":"Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68(2):270\u201381.","journal-title":"Neuron"},{"issue":"7409","key":"447_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488(7409):96\u20139.","journal-title":"Nature"},{"issue":"10","key":"447_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40266-016-0406-x","volume":"33","author":"J Liu","year":"2016","unstructured":"Liu J, et al. Antibody-based drugs and approaches against amyloid-beta species for Alzheimer\u2019s disease immunotherapy. Drugs Aging. 2016;33(10):685\u201397.","journal-title":"Drugs Aging"},{"key":"447_CR5","volume-title":"Merck announces discontinuation of APECS study evaluating verubecestat [MK-8931] for the treatment of people with prodromal Alzheimer\u2019s Disease","author":"MerckMSD","year":"2018","unstructured":"MerckMSD, Merck announces discontinuation of APECS study evaluating verubecestat [MK-8931] for the treatment of people with prodromal Alzheimer\u2019s Disease. 2018."},{"issue":"6","key":"447_CR6","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer\u2019s disease. Neuron. 2013;80(6):1347\u201358.","journal-title":"Neuron"},{"issue":"7618","key":"447_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"1","key":"447_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28(1):49\u201369.","journal-title":"J Alzheimers Dis"},{"key":"447_CR9","doi-asserted-by":"crossref","unstructured":"Voyle N, et al.\u00a0The effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (CSF) in the Marguerite Road Study. Alzheimer\u2019s Assoc Int Congr. 2018:Abst ID23224.","DOI":"10.1016\/j.jalz.2018.06.2379"},{"key":"447_CR10","volume-title":"Eisai and Biogen announce detailed results of phase II clinical study of BAN2401 in early Azheimer\u2019s disease at Alzheimer\u2019s Association International Conference (AAIC) 2018","author":"Eisai","year":"2018","unstructured":"Eisai, Eisai and Biogen announce detailed results of phase II clinical study of BAN2401 in early Azheimer\u2019s disease at Alzheimer\u2019s Association International Conference (AAIC) 2018. 2018."},{"key":"447_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuint.2017.08.010","volume":"119","author":"Kenjiro Ono","year":"2018","unstructured":"Ono K. Alzheimer\u2019s disease as oligomeropathy. Neurochem Int. 2017;119:57-70","journal-title":"Neurochemistry International"},{"issue":"6","key":"447_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1999;46(6):860\u20136.","journal-title":"Ann Neurol"},{"issue":"3","key":"447_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue LF, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol. 1999;155(3):853\u201362.","journal-title":"Am J Pathol"},{"issue":"1","key":"447_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.23748","volume":"73","author":"TJ Esparza","year":"2013","unstructured":"Esparza TJ, et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73(1):104\u201319.","journal-title":"Ann Neurol"},{"issue":"8","key":"447_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837\u201342.","journal-title":"Nat Med"},{"issue":"14","key":"447_CR16","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1073\/pnas.1017033108","volume":"108","author":"M Jin","year":"2011","unstructured":"Jin M, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108(14):5819\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"447_CR17","doi-asserted-by":"publisher","first-page":"e32014","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin D, et al. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2):e32014.","journal-title":"PLoS One"},{"issue":"5","key":"447_CR18","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.neurobiolaging.2012.10.028","volume":"34","author":"GG Borlikova","year":"2013","unstructured":"Borlikova GG, et al. Alzheimer brain-derived amyloid beta-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging. 2013;34(5):1315\u201327.","journal-title":"Neurobiol Aging"},{"key":"447_CR19","doi-asserted-by":"publisher","first-page":"38187","DOI":"10.1038\/srep38187","volume":"6","author":"TJ Esparza","year":"2016","unstructured":"Esparza TJ, et al. Soluble amyloid-beta aggregates from human Alzheimer\u2019s disease brains. Sci Rep. 2016;6:38187.","journal-title":"Sci Rep"},{"issue":"1","key":"447_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1523\/JNEUROSCI.1698-16.2016","volume":"37","author":"T Yang","year":"2017","unstructured":"Yang T, et al. Large soluble oligomers of amyloid beta-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. J Neurosci. 2017;37(1):152\u201363.","journal-title":"J Neurosci"},{"issue":"1","key":"447_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-017-0293-3","volume":"9","author":"DL Brody","year":"2017","unstructured":"Brody DL, et al. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):62.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"447_CR22","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/brain\/awx057","volume":"140","author":"BR Roberts","year":"2017","unstructured":"Roberts BR, et al. Biochemically-defined pools of amyloid-beta in sporadic Alzheimer\u2019s disease: correlation with amyloid PET. Brain. 2017;140(5):1486\u201398.","journal-title":"Brain"},{"issue":"8","key":"447_CR23","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage MJ, et al. A sensitive abeta oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J Neurosci. 2014;34(8):2884\u201397.","journal-title":"J Neurosci"},{"issue":"1","key":"447_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-015-0100-y","volume":"7","author":"T Yang","year":"2015","unstructured":"Yang T, et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther. 2015;7(1):14.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"447_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JAD-151029","volume":"53","author":"J Schuster","year":"2016","unstructured":"Schuster J, Funke SA. Methods for the specific detection and quantitation of amyloid-beta oligomers in cerebrospinal fluid. J Alzheimers Dis. 2016;53(1):53\u201367.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"447_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/acn3.469","volume":"4","author":"JJ Mo","year":"2017","unstructured":"Mo JJ, et al. Efficacy and safety of anti-amyloid-beta immunotherapy for Alzheimer\u2019s disease: a systematic review and network meta-analysis. Ann Clin Transl Neurol. 2017;4(12):931\u201342.","journal-title":"Ann Clin Transl Neurol"},{"issue":"21","key":"447_CR27","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","volume":"90","author":"JL Cummings","year":"2018","unstructured":"Cummings JL, et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889\u201397.","journal-title":"Neurology"},{"issue":"1","key":"447_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/187152709787601830","volume":"8","author":"TE Golde","year":"2009","unstructured":"Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets. 2009;8(1):31\u201349.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"37","key":"447_CR29","doi-asserted-by":"publisher","first-page":"14052","DOI":"10.1073\/pnas.0805902105","volume":"105","author":"N Schupf","year":"2008","unstructured":"Schupf N, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2008;105(37):14052\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"447_CR30","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.4049\/jimmunol.164.4.1925","volume":"164","author":"MP Reddy","year":"2000","unstructured":"Reddy MP, et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol. 2000;164(4):1925\u201333.","journal-title":"J Immunol"},{"issue":"8","key":"447_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"447_CR32","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1111\/j.1742-4658.2006.05263.x","volume":"273","author":"AS Johansson","year":"2006","unstructured":"Johansson AS, et al. Physiochemical characterization of the Alzheimer\u2019s disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J. 2006;273(12):2618\u201330.","journal-title":"FEBS J"},{"issue":"13","key":"447_CR33","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1074\/jbc.M210207200","volume":"278","author":"WB Stine Jr","year":"2003","unstructured":"Stine WB Jr, et al. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278(13):11612\u201322.","journal-title":"J Biol Chem"},{"issue":"1","key":"447_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0014-4886(03)00252-8","volume":"184","author":"V Blanchard","year":"2003","unstructured":"Blanchard V, et al. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP\/PS1 transgenic mice. Exp Neurol. 2003;184(1):247\u201363.","journal-title":"Exp Neurol"},{"issue":"17","key":"447_CR35","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1523\/JNEUROSCI.20-17-06452.2000","volume":"20","author":"I Dewachter","year":"2000","unstructured":"Dewachter I, et al. Aging increased amyloid peptide and caused amyloid plaques in brain of old APP\/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci. 2000;20(17):6452\u20138.","journal-title":"J Neurosci"},{"issue":"8","key":"447_CR36","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nprot.2009.89","volume":"4","author":"A Holtmaat","year":"2009","unstructured":"Holtmaat A, et al. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc. 2009;4(8):1128\u201344.","journal-title":"Nat Protoc"},{"issue":"3","key":"447_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00401-010-0787-6","volume":"121","author":"S Burgold","year":"2011","unstructured":"Burgold S, et al. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol. 2011;121(3):327\u201335.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"447_CR38","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.4049\/jimmunol.131.5.2178","volume":"131","author":"DB Wilde","year":"1983","unstructured":"Wilde DB, et al. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol. 1983;131(5):2178\u201383.","journal-title":"J Immunol"},{"issue":"12","key":"447_CR39","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.4049\/jimmunol.144.12.4587","volume":"144","author":"SE Alters","year":"1990","unstructured":"Alters SE, et al. Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies. J Immunol. 1990;144(12):4587\u201392.","journal-title":"J Immunol"},{"issue":"3","key":"447_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","volume":"25","author":"MM Racke","year":"2005","unstructured":"Racke MM, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25(3):629\u201336.","journal-title":"J Neurosci"},{"issue":"44","key":"447_CR41","doi-asserted-by":"publisher","first-page":"45897","DOI":"10.1074\/jbc.M407668200","volume":"279","author":"J Ghiso","year":"2004","unstructured":"Ghiso J, et al. Systemic catabolism of Alzheimer\u2019s Abeta40 and Abeta42. J Biol Chem. 2004;279(44):45897\u2013908.","journal-title":"J Biol Chem"},{"issue":"50","key":"447_CR42","doi-asserted-by":"publisher","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","volume":"36","author":"KV Kastanenka","year":"2016","unstructured":"Kastanenka KV, et al. Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice. J Neurosci. 2016;36(50):12549\u201358.","journal-title":"J Neurosci"},{"issue":"3","key":"447_CR43","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1523\/JNEUROSCI.4936-10.2011","volume":"31","author":"N Beckmann","year":"2011","unstructured":"Beckmann N, et al. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer\u2019s disease: application to passive Abeta immunotherapy. J Neurosci. 2011;31(3):1023\u201331.","journal-title":"J Neurosci"},{"issue":"5","key":"447_CR44","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00401-015-1484-2","volume":"130","author":"JP Fuller","year":"2015","unstructured":"Fuller JP, et al. Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta Neuropathol. 2015;130(5):699\u2013711.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"447_CR45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"447_CR46","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow K, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69(8):1002\u201310.","journal-title":"Arch Neurol"},{"issue":"12","key":"447_CR47","doi-asserted-by":"publisher","first-page":"E506","DOI":"10.1002\/ajh.24563","volume":"91","author":"MA Gertz","year":"2016","unstructured":"Gertz MA, Landau HJ, Weiss BM. Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody. Am J Hematol. 2016;91(12):E506\u20138.","journal-title":"Am J Hematol"},{"key":"447_CR48","volume-title":"High-dose gantenerumab lowers plaque load","author":"AlzForumNews","year":"2017","unstructured":"AlzForumNews, High-dose gantenerumab lowers plaque load. 2017."},{"issue":"4","key":"447_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement"},{"issue":"18","key":"447_CR50","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","volume":"22","author":"BJ Bacskai","year":"2002","unstructured":"Bacskai BJ, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002;22(18):7873\u20138.","journal-title":"J Neurosci"},{"issue":"2","key":"447_CR51","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.nbd.2005.04.007","volume":"20","author":"Y Tamura","year":"2005","unstructured":"Tamura Y, et al. The F(ab)\u20192 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol Dis. 2005;20(2):541\u20139.","journal-title":"Neurobiol Dis"},{"issue":"46","key":"447_CR52","doi-asserted-by":"publisher","first-page":"11923","DOI":"10.1523\/JNEUROSCI.2795-06.2006","volume":"26","author":"Y Levites","year":"2006","unstructured":"Levites Y, et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006;26(46):11923\u20138.","journal-title":"J Neurosci"},{"issue":"24","key":"447_CR53","doi-asserted-by":"publisher","first-page":"8532","DOI":"10.1523\/JNEUROSCI.23-24-08532.2003","volume":"23","author":"P Das","year":"2003","unstructured":"Das P, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma\u2212\/\u2212 knock-out mice. J Neurosci. 2003;23(24):8532\u20138.","journal-title":"J Neurosci"},{"issue":"20","key":"447_CR54","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1523\/JNEUROSCI.0695-06.2006","volume":"26","author":"DM Wilcock","year":"2006","unstructured":"Wilcock DM, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26(20):5340\u20136.","journal-title":"J Neurosci"},{"issue":"28","key":"447_CR55","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci. 2012;32(28):9677\u201389.","journal-title":"J Neurosci"},{"issue":"1","key":"447_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-016-0177-y","volume":"8","author":"M Delnomdedieu","year":"2016","unstructured":"Delnomdedieu M, et al. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8(1):12.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"447_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbi.2010.10.015","volume":"25","author":"R Yirmiya","year":"2011","unstructured":"Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun. 2011;25(2):181\u2013213.","journal-title":"Brain Behav Immun"},{"issue":"6","key":"447_CR58","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","volume":"16","author":"SH Lee","year":"2016","unstructured":"Lee SH, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016;16(6):1690\u2013700.","journal-title":"Cell Rep"},{"issue":"24","key":"447_CR59","doi-asserted-by":"publisher","first-page":"9758","DOI":"10.1073\/pnas.1218402110","volume":"110","author":"SI Cohen","year":"2013","unstructured":"Cohen SI, et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A. 2013;110(24):9758\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"447_CR60","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1038\/ncomms7176","volume":"6","author":"C Condello","year":"2015","unstructured":"Condello C, et al. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun. 2015;6:6176.","journal-title":"Nat Commun"},{"issue":"11","key":"447_CR61","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1523\/JNEUROSCI.5077-10.2011","volume":"31","author":"A Wang","year":"2011","unstructured":"Wang A, et al. Robust amyloid clearance in a mouse model of Alzheimer\u2019s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci. 2011;31(11):4124\u201336.","journal-title":"J Neurosci"},{"issue":"35","key":"447_CR62","doi-asserted-by":"publisher","first-page":"11621","DOI":"10.1523\/JNEUROSCI.1405-14.2014","volume":"34","author":"H Jacobsen","year":"2014","unstructured":"Jacobsen H, et al. Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci. 2014;34(35):11621\u201330.","journal-title":"J Neurosci"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0447-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:10:36Z","timestamp":1694106636000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0447-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0447-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies have been validated by an internal ethics committee (see Methods section).Experiments were performed at Sanofi in an AAALAC-accredited facility in full compliance with the standards for the care and use of laboratory animals, according to French and European Community (Directive 2010\/63\/EU) legislation. All procedures were approved by the local Animal Ethics Committee (CEEA #24) and the French Ministry for Research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HK and JR are inventors on patent application W02009\/065054 describing the murine antibody 13C3 from which the antibodies described in this manuscript are derived. Sanofi hold a license to the derived intellectual property. LK, Neurotar Ltd., performed this work as part of a research contract with Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"117"}}